

# Ovarian capillary hemangioma and stromal luteinization: a case study with hormonal receptor evaluation

D. Miliaras<sup>1,3</sup>, M.D.; S. Papaemmanouil<sup>1</sup>, M. D.; G. Blatzas<sup>2</sup>, M.D.

<sup>1</sup>Department of Pathology, and <sup>2</sup>Division of Surgery, General Clinic of Thessaloniki, and <sup>3</sup>Laboratory of Histology and Embryology, Medical Faculty, Aristotelian University, Thessaloniki (Greece)

## Summary

**Background:** Ovarian hemangiomas are rare tumors, most of them asymptomatic, and of the cavernous type. Six of the reported cases were accompanied by stromal luteinization. There is a debate whether these luteinized cells promote the growth of the vascular lesion or just represent a stromal reaction.

**Case:** A 71-year-old female was incidentally found to have a small capillary hemangioma in her left ovary, surrounded by a rim of luteinized stromal cells. Immunohistochemical investigation revealed the presence of estrogen and progesterone receptors in the endothelial cells of the lesion.

**Conclusion:** Our histological and immunohistochemical findings, as well as data from the literature, support the view that at least some vascular lesions may result from hormonal stimulation.

**Key words:** Ovarian hemangioma; Stromal luteinization; Estrogen receptors; Progesterone receptors.

## Introduction

Vascular tumors of the female genital tract, and especially those of the ovary, are extremely rare. Approximately 50 cases of ovarian hemangiomas have been reported in the literature [1-4]. In some patients ovarian hemangiomas occur together with diffuse abdominopelvic hemangiomatosis, while others represent isolated ovarian masses [5]. The former patients often have concomitant abdominal or pelvic symptoms, whereas the latter are usually asymptomatic. This article describes a 71-year-old woman with an asymptomatic ovarian hemangioma surrounded by stromal luteinization.

## Case Report

A 71-year-old Caucasian woman was subjected to rectosigmoidectomy in our Institution for rectal cancer. During this operation both ovaries were also resected because the right one was bearing a cyst, while the left was very close to the rectal tumor and was excised for staging purposes. The patient did not have any symptoms from her genital tract (e.g. metrorrhagia) or any other endocrinological manifestations.

**Pathologic Findings.** For histological examination we delivered a segment of the left colon, 16 cm in length. One centimeter from the lower resection margin, the large intestine revealed ulcerated tumor with irregular borders, 4 cm in diameter. Ten lymph nodes, 0.3-1.2 cm in diameter were removed from the pericolonic fat tissue. In addition, for histological examination, proximal and distal intestinal rings, two lymph nodes from the root of the left mesenteric artery, and both uterine adnexae were analyzed. The left ovary measured 2.5x1.5x1.1 cm and in cross section showed a relatively circumscribed lesion, 0.8 cm in diameter, with an orange-colored peripheral rim and hemorrhagic central portion. These features macroscopically suggested a corpus luteum. The right ovary measured 4x3.5x2

cm and in cross section showed a cyst, 2.5 cm in diameter with a smooth internal surface and brownish lining.

Microscopically the intestinal tumor represented a well-differentiated colonic adenocarcinoma invading only the submucosa. Resection margins, as well as all examined lymph nodes, were free of tumor (according to AJCC: pT1, N0). In the left ovary we found that what looked like a corpus luteum was actually a benign vascular lesion. It consisted of masses of bland endothelial cells which frequently formed numerous capillary blood vessels (Figure 1). Cellular atypia or significant mitotic activity were not observed. Along the margin of this well-circumscribed capillary hemangioma there was a layer of luteinized cells which formed a capsule enclosing the lesion. The rest of the right ovary was atrophic. The left ovary displayed an endometriotic cyst which was partially lined by one layer of ciliated cuboidal cells with no atypia and partially by many layers of iron-laden macrophages. Small inclusion cysts and corpora albicantia were also observed in the left ovary.




Figure 1. — Typical capillary hemangioma on the lower left side and prominent luteinization of the adjacent stroma on the upper right side. H&E x100.

Revised manuscript accepted for publication April 16, 2001




Figure 2. — Positive reaction to estrogen receptor antibody of the nuclei of the endothelial (left), and the luteinized cells (right). DAB x400.

Immunohistochemical investigation of the hemangioma for presence of hormonal receptors was performed using a streptavidin-biotin detection method («Unitect», Oncogene Research Products, Boston, U.S.A.) with high temperature pretreatment, and monoclonal antibodies against estrogen and progesterone receptors (both 1:80 dilution, Novocastra Laboratories Ltd., Newcastle upon Tyne, U.K.). The nuclei of the endothelial cells were moderately positive for both antibodies (Figure 2). The nuclei of the surrounding luteinized cells were also moderately positive. The ovarian stroma presented more intense reactions to both antibodies.

## Discussion

Ovarian hemangiomas are rare tumors, mostly of the cavernous type [1-4]. More commonly they are small and remain asymptomatic until found incidentally. However, when they have large dimensions, they may give rise to symptoms as any large ovarian tumor. In addition, very few of the reported cases were accompanied by ascites [1, 3, 4]. Magnetic resonance imaging is very useful for the presurgical evaluation of these tumors.

Our case concerned a small hemangioma, which was an incidental pathological finding in an operation that was performed for rectal tumor excision. The interesting and particular characteristics of the case presented here are the type of hemangioma, which was capillary, and the presence of a rim of luteinized cells surrounding the lesion. The presence of these luteinized cells in a close and presumably causal relation with this benign vascular lesion, is for one more reason intriguing, because it was found in a postmenopausal woman. Six similar cases presenting a capillary hemangioma and luteinization of the ovarian stroma have been described in the literature [1-4]. Five also involved postmenopausal women. Furthermore, two of these tumors were very large, accompanied by ascites and elevated levels of CA-125 in the serum [3-4]. Ovarian pathology occurred together with a synchronous well-differentiated endometrial adenocarcinoma in another of these six cases [2], while one

more case presented simultaneously mild complex endometrial hyperplasia [1]. Endometrial hyperplasia and adenocarcinoma in these particular cases may be related to hormonal stimulation by the ovarian luteinized cells, since luteinized cells produce androgens which may consecutively transform to estrogens in the adipose tissue. However, it should be noted that the patient with endometrial adenocarcinoma had bilateral diffuse stromal luteinization which is usually described as hyperthecosis, rather than unilateral, focal luteinization limited to the stroma surrounding the ovarian hemangioma, as in our case.

The main issue regarding these six cases, as well as ours, is if there is any causal relationship between these capillary ovarian hemangiomas and the luteinized stromal cells, which in some instances were found in close contact. One possible explanation is that these luteinized cells promote the growth of vascular lesions. The angiotropic effect of estrogens is well established. They may induce the growth of vascular neoplasms, as for example hepatic hemangioendotheliomas in women receiving oral contraceptives [6]. In addition, estrogens, while they are capable of promoting neo-vascularization in proliferating endometrium, may also have an antiproliferative effect on other vessels (such as coronary and carotid arteries), an inhibitory effect of great clinical importance in certain vasculopathies [7]. There is evidence that this hormonal angiotropic effect, at least in the endometrium, may be exerted indirectly, i.e. via release of vascular endothelial growth factor by the endometrial cells [8]. However, other investigators have recently found plasma membrane binding sites for estradiol in human vascular endothelial cells which mediate rapid intracellular signaling [9]. The immunohistochemical findings of our case are in accordance with these data where a positive reaction of the endothelial cells against antibodies to estrogen and progesterone receptors was observed. This is the first case of ovarian hemangioma accompanied by stromal luteinization where such an investigation was performed.

On the contrary while a hyperestrogenic state in females is not uncommon, vascular tumors of the ovary are very rare. It should also be kept in mind that foci of stromal luteinization have been observed as a form of reaction in various ovarian neoplasms, mostly primary epithelial and germ cell tumors, as well as metastatic tumors [10]. Finally, the possibility of hormonal-dependency of ovarian hemangiomas, as well as of other vascular tumors generally, is an issue that requires further study.

## References

- [1] Savargaonkar P. R., Wells S., Graham I., Buckley C. H.: "Ovarian hemangiomas and stromal luteinization". *Histopathology*, 1994, 25, 185.
- [2] Carder P. J., Goudlesbrough D. R.: "Ovarian hemangiomas and stromal luteinization". *Histopathology*, 1995, 26, 585.
- [3] Gehring P. A., Fowler W. C., Lininger R. A.: "Ovarian capillary hemangioma presenting as an adnexal mass with massive ascites and elevated CA-125". *Gynecol. Oncol.*, 2000, 76, 130.

- [4] Yamawaki T., Hirai Y., Takeshima N., Hasumi K.: "Ovarian hemangioma associated with concomitant stromal luteinization and ascites". *Gynecol. Oncol.*, 1996, 61, 438.
- [5] Lawhead R. A., Copeland L. J., Edwards C. L.: "Bilateral ovarian hemangiomas associated with diffuse abdominopelvic hemangiomatosis". *Obstet. Gynecol.*, 1985, 65, 597.
- [6] Dean P. J., Haggitt R. C., O'Hara C. J.: "Malignant epithelioid hemangioendothelioma of the liver in young women: relationship to oral contraceptive use". *Am. J. Surg. Pathol.*, 1985, 9, 695.
- [7] Makela S., Savolainen H., Aavik E., Myllarniemi M., Strauss L., Taskinen E. *et al.*: "Differentiation between vasculoprotective and uterotrophic effects of ligands with different binding affinities to estrogen receptors  $\alpha$  and  $\beta$ ". *Proc. Natl. Acad. Sci. U.S.A.*, 1999, 96, 7077.
- [8] Mueller M. D., Vigne J.-L., Minchenko A., Lebovic D. I., Leitman D. C., Taylor R. N.: "Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors  $\alpha$  and  $\beta$ ". *Proc. Natl. Acad. Sci. U.S.A.*, 2000, 97, 10972.
- [9] Russell K. S., Haynes M. P., Sinha D., Clerisme E., Bender J. R.: "Human vascular endothelial cells contain membrane binding sites for estradiol, which mediate rapid intracellular signaling". *Proc. Natl. Acad. Sci. U.S.A.*, 2000, 97, 5930.
- [10] Scully R.E.: "Ovarian tumours with functioning stroma". In: Fox H. (ed.): *Obstetrical & Gynaecological Pathology*, 3<sup>rd</sup> ed. Churchill Livingstone, Edinburgh, 1987, 724.

Address reprint requests to:  
D. MILIARAS, M.D.  
75 Tsimiski Street  
Thessaloniki GR54622  
(Greece)

## CME Journal of Gynecologic Oncology

An International Journal for Continuing Medical Education on Basic and Clinical Gynecologic Oncology

Editor-in-Chief: Péter Bószé

Associate Editor: George D. Wilbanks - Managing Editor: Terézia Barabás

PRIMED-X PRESS - BUDAPEST

Editorial Office: 1301 Budapest, P. O. Box 46, Hungary - Tel./Fax: (36 1) 275 21272

E-mail address: bosze@mail.matav.hu - ISSN: 12199087

### PUBLISHED AND FORTHCOMING CHAPTERS

#### *Published Chapters*

• Hormone replacement therapy (HRT) and cancer. *Editor William T. Creasman, M.D.* • Techniques of urinary diversion in Gynecologic Oncology. *Editor Javier F. Magrina, M.D.* • Granulosa cell tumors of the ovary. *Editor Péter Bószé, M.D.* • Genetics for Gynecologic Oncologists (part 1). *Editor Péter Bószé, M.D.* • Genetics for Gynecologic Oncologists (part 2). *Editor Péter Bószé, M.D.* • Endodermal sinus tumors (yolk sac tumors) of the ovary. *Editor Peter E. Schwartz, M.D.* • The parametrium and paracolpium. An anatomic and surgical symposium with emphasis on the cardinal ligament as it relates to radical hysterectomy. *Editor C. Paul Morrow, M.D.* • Malignant melanoma of the vulva. *Editor Spyros Retsas, M.D.* • Genetics for Gynecologic Oncologists (part 3). *Editor Péter Bószé, M.D.* • Paclitaxel in breast cancer and gynaecological tumours. *Editor Jan Neijt, M.D.* • Fertility drugs and the risk of gynecological tumours. *Editor Jan Neijt, M.D.* • Current status of intraperitoneal chemotherapy in the management of epithelial ovarian carcinoma. *Editor Murie Markman, M.D.* • Neoadjuvant chemotherapy in the treatment of carcinoma of the uterine cervix. *Editor Guillermo R. di Paola, M.D.* • Stage IIB cervical carcinoma. *Editor Heung-Tat Ng, M.D.* • Teratomas of the ovary. *Editor Péter Bószé, M.D.* • Prognostic factors in epithelial ovarian carcinoma (part 1). *Editor Péter Bószé, M.D.* • Prognostic factors in epithelial ovarian carcinoma (part 2). *Editor Péter Bószé, M.D.* • Global challenge of cervical cancer screening and prevention. *Editor Joseph Monsonogo, M.D.* • Paraaortic nodes:

involvement in Gynaecological Oncology. *Editor Pierluigi Benedetti Panici, M.D.* • New techniques and assessment of gynaecological tumours. *Editors Harold Fox, M.D. and Michael Wells, M.D.* • Guidelines from the Biomed 2 familial breast cancer demonstration project. "Audit of a new development in medical practice in European centres". *Editors Neva E. Haites, M.D., Iain Brown, PhD, Benedict J. Milner, Ph.D.* • Cytotoxic drug therapy in Gynaecological Oncology: principles and practice (part 1). *Editor Péter Bószé, M.D.* • Cytotoxic drug therapy in Gynaecological Oncology: principles and practice (part 2). *Editor Péter Bószé, M.D.* • Prognostic factors in carcinoma of the uterine cervix. *Editor Péter Bószé, M.D.* • Laparoscopic treatment of cervical and endometrial cancer. *Editor Javier F. Magrina, M.D.*

#### *Forthcoming Chapters*

• Controversies and new trends in FIGO staging. *Editor John L. Benedet, M.D.* • Palliative care in Gynecologic and breast cancer. *Editor A. Peter M. Heintz, M.D.* • Urinary function in relation to and following treatment of gynaecological malignancies. *Editor Ulf Ulmsten, M.D.* • Fertility drugs, in vitro fertilisation and the risk of gynaecological malignancies. *Editor Curt W. Burger, M.D.* • Current status of fertility sparing treatment in invasive gynecologic malignancies. *Editor Michel Roy, M.D.* • Gynecologic Oncology protocols: endometrial cancer. *Editor Péter Bószé, M.D.* • Management of recurrent epithelial ovarian cancer. *Editor Jan B. Vermorken, M.D.* • Ovarian metastases from colorectal cancer. *Editor Niall O'Higgins, M.D.* • Angiogenesis: clinical implications in Gynecologic Oncology. *Editor Michael Höckel, M.D.*

### *Obtain the novel approach shaping the future of continuing medical education*

The CME Journal of Gynecologic Oncology focuses on controversial issues and new developments in gynecologic oncology with the aim of providing a unique opportunity for those interested in subspecialty training and postgraduate education in gynecologic oncology. The journal is not a venue for original articles, but contains chapters each devoted to a single topic addressed by several internationally acknowledged, exclusively invited experts and edited by an individual distinguished in the field. Practical conclusions and guidelines are given by the Chapter Editor. News, comments, critiques, book reviews and letters are also provided.